CN
CNTX.US Context Therapeutics Inc
- Market cap
- USD 16.6M
- P/E
- -
- P/B
- 0.59x
- ROE
- -132.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CNTX.US undervalued?
Graham numberThe Graham number of Context Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Context Therapeutics Inc fundamental analysis
No fundamental analysis for Context Therapeutics Inc yet.
Context Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The comp…
Full company profileContext Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Context Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | - | - | - | -9.27K | -12.0K | -52.7K | -125K | - |
| Operating Income | -33.2M | -24.1M | -5.38M | -2.57M | -10.5M | -15.4M | -25.1M | -29.9M | -39.7M | -43.0M |
| EBITDA | - | - | -5.38M | -2.57M | -10.5M | -14.9M | -24.0M | -26.7M | -36.1M | -41.1M |
| Net Income | -37.7M | -24.6M | -7.48M | 6.64M | -10.5M | -14.8M | -24.0M | -26.7M | -36.1M | -41.2M |
| EPS | - | - | -0.68 | 0.61 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 | -0.43 |
| Balance Sheet | ||||||||||
| Total Assets | 24.0M | 68.3M | 274K | 467K | 51.3M | 38.0M | 16.1M | 98.1M | 68.5M | 36.5M |
| Total Liabilities | 10.9M | 9.39M | 24.2M | 17.4M | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M | 5.53M |
| Shareholders' Equity | 13.1M | 59.0M | -24.0M | -16.9M | 48.3M | 34.8M | 11.9M | 95.3M | 60.5M | 31.0M |
| Cash & Short-term Investments | 16.2M | 60.7M | 227K | 341K | 49.6M | 35.5M | 14.4M | 94.4M | 66.0M | 34.4M |
| Total Debt | - | - | 21.8M | 5.95M | - | 55.1K | - | 219K | 112K | 207K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -30.6M | -22.3M | -2.84M | -1.03M | -8.80M | -13.5M | -21.0M | -14.6M | -26.4M | -33.4M |
| Capital Expenditure | 28.0K | 28.0K | 0.00 | 0.00 | 250K | 537K | 0.00 | 14.8M | 33.9K | 2.74M |
| Free Cash Flow | - | - | -2.84M | -1.03M | -9.05M | -14.1M | -21.0M | -29.3M | -26.4M | -33.4M |
| Ratios | ||||||||||
| ROE | -287.2% | -41.8% | - | - | -21.7% | -42.7% | -201.9% | -28.1% | -59.7% | -132.7% |
| ROA | -156.9% | -36.0% | -2,736.1% | 1,421.8% | -20.4% | -39.1% | -149.2% | -27.2% | -52.7% | -112.6% |
| Debt to Equity | - | - | - | - | - | 0.00x | - | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Context Therapeutics Inc dividends
Context Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Context Therapeutics Inc
- Insiders 1.57%
- Institutions 67.48%
- Public & others 30.95%
- Shares outstanding 91.9M
- Free float 63.7M
Top funds holding CNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.82M | 3.06% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.28M | 2.48% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 1.20M | 1.31% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.05M | 1.14% | +3.99% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 885K | 0.96% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 534K | 0.58% | -1.26% | Sep 2026 |
| Abante Quant Value FI | 412K | 0.45% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 284K | 0.31% | 0.00% | Oct 2026 |
| Calamos Market Neutral Income A | 278K | 0.30% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 276K | 0.30% | -0.38% | Sep 2026 |
| Belfund SICAV Belinvest Equity A USD Acc | 260K | 0.28% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 228K | 0.25% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 203K | 0.22% | 0.00% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 160K | 0.17% | 0.00% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 126K | 0.14% | 0.00% | Aug 2026 |
| EQ/2000 Managed Volatility IB | 104K | 0.11% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 Growth ETF | 101K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 97.6K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth Index | 97.5K | 0.11% | -2.13% | Aug 2026 |
Top institutions holding CNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 7.42M | 8.08% | 0.00% | Jun 2026 |
| Nextech Invest, Ltd. | 7.42M | 8.08% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 7.06M | 7.69% | +1.44% | Jun 2026 |
| BlackRock Inc | 6.17M | 6.71% | +628.63% | Jun 2026 |
| Avidity Partners Management LP | 5.00M | 5.44% | -50.00% | Jun 2026 |
| Franklin Templeton Inc | 3.80M | 4.14% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.43M | 3.74% | +0.00% | Jun 2026 |
| Octagon Capital Advisors LP | 3.05M | 3.32% | -41.90% | Jun 2026 |
| Blue Owl Capital Holdings LP | 2.93M | 3.19% | -42.35% | Jun 2026 |
| TCG Crossover Management, LLC | 2.68M | 2.92% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.83M | 1.99% | +203.15% | Jun 2026 |
| State Street Corp | 1.41M | 1.54% | +505.30% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.30M | 1.41% | -87.84% | Jun 2026 |
| Renaissance Technologies Corp | 1.04M | 1.13% | +469.07% | Jun 2026 |
| Acadian Asset Management LLC | 1.01M | 1.10% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 751K | 0.82% | +113.89% | Jun 2026 |
| Jane Street Group LLC | 645K | 0.70% | +47.67% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 639K | 0.70% | 0.00% | Jun 2026 |
| Northern Trust Corp | 616K | 0.67% | +496.16% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 434K | 0.47% | +27.11% | Jun 2026 |
Context Therapeutics Inc company profile
- Company name
- Context Therapeutics Inc
- Ticker
- CNTX.US
- Exchange
- USA Stocks
- Listed since
- Oct 20, 2021
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 15
- Fiscal year end
- December
- Address
- 2001 Market Street, Philadelphia, PA, United States, 19103
- Phone
- 267 225 7416
- Website
- contexttherapeutics.com
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc management
7- Mr. Martin A. LehrCo-Founder, President, CEO & Director · born 1984
- Ms. Jennifer Minai-AzaryCFO & Treasurer · born 1978
- Mr. Alex C. Levit Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1979
- Mr. Christopher Beck M.B.A.Senior Vice President of Operations
- Mr. Jeffrey LiebmanAssociate Director of Accounting
- Ms. Jennifer Dashnau M.B.A., Ph.D.Senior Vice President of Technical Operations
- Dr. Karen Chagin M.D.Chief Medical Officer · born 1977